News

The company’s loss from operations for the second quarter of 2011 was $6.28m, compared to $5.36m for the same period in 2010. For the six months ended 30

AZ-004 is indicated as a treatment of agitation in patients with schizophrenia or bipolar disorder. In the original CRL, the Center for Drug Evaluation and Research of FDA

The new name aligns with the company’s core technology – transdermal absorption of pharmaceutical agents. Promescent, which employs a proprietary, eutectic mixture of lidocaine and other compounds, delivers

Sohm has rolled out the products through its Indian manufacturing and marketing facility under Diorac brand name. Sohm CEO Shailesh Shah said Diorac is a combination of prebiotic

The drug, which is a solution formulation, has been approved in 200mg, 1gm and 2gm with a concentration of 38 mg/ml strength. The company expects to roll out

As per the agreement, the holders of Emdeon common stock are expected to get around $19 per share in cash. Following the merger, Emdeon will become a privately

Firefly will utilize the grant to braden its production capacity and also to assess its microRNA assay. MicroRNAs are a class of biomarkers which are used as indicators

Dyadic’s net loss was $736,204, or $0.02 loss per diluted share, compared to $1.41m, or $0.05 per diluted share, for the same period in 2010. The company’s loss

The trial aims to compare the effectiveness and safety of conventional therapy treatment plus ecallantide to conventional therapy treatment plus placebo in 176 patients recruited at 40 US